PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Pegloticase - Hyperuricaemia and Gout

PAD Profile : Pegloticase - Hyperuricaemia and Gout

Brand Names Include :
Krystexxa

Traffic Light Status

Status 1 of 1.

Status :
Non Formulary
Formulations :
  • Not Specified
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
NFD1
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

Type
Document
Review Date

Committee Recommendations

Date
Committee Name
Narrative
05 September 2018
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Prescribing Clinical Network does not recommend the use of pegloticase for treating severe debilitating chronic tophaceous gout, as its marketing authorisation has been withdrawn in the UK/EU.

See Pegloticase policy statement below for further details

31 July 2013
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
Not recommended for use by NICE guidance TA291. See attached NICE guidance for further information

Associated BNF Codes

10. Musculoskeletal and Joint Diseases
10.01.04. Gout and cytotoxic induced hyperuicaemia
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More